Neuronal Nitric Oxide Synthase (nNOS, NOS1) Rs693534 and Rs7977109 Variants and Risk for Restless Legs Syndrome

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2014 Oct 11

PMID 25300364

Citations 13

Authors

Felix Javier Jimenez-Jimenez

Hortensia Alonso-Navarro

Carmen Martinez

Martin Zurdo

Laura Turpin-Fenoll

Jorge Millan-Pascual

Teresa Adeva-Bartolome

Esther Cubo

Francisco Navacerrada

Ana Rojo-Sebastian

Lluisa Rubio

Marisol Calleja

Jose Francisco Plaza-Nieto

Belen Pilo-De-La-Fuente

Margarita Arroyo-Solera

Esteban Garcia-Albea

Elena Garcia-Martin

Jose A G Agundez

Affiliations

Soon will be listed here.

Abstract

Several biochemical, neuropathological, and experimental data suggest a possible role of nitric oxide (NO) in the pathophysiology of restless legs syndrome (RLS). Two single nucleotide polymorphisms (SNPs) neuronal nitric oxide synthase (nNOS or NOS1) gene (rs7977109 and rs693534) have been found to be associated with the risk for RLS in Germans, although only one of them (rs7977109) remained as significant after multiple comparison tests. The aim of our study was to replicate the possible association between these SNPs and risk for RLS in the Spanish population. We studied the allelic and genotype frequencies of the SNPs rs7977109 and rs693534 in 205 patients with RLS and 328 healthy controls using TaqMan genotyping. The rs7977109 and rs693534 genotypes and allelic frequencies did not significantly differ between patients with RLS and controls and were unrelated with the age at onset of RLS, gender, ferritin levels, and response to dopaminergic or gabaergic agents. The rs7999109GA genotype was overrepresented in RLS patients with positive family history of RLS, and in patients with symptomatic response to clonazepam. The results of our study suggest that these two NOS1 SNPs are not related to the overall risk for RLS in the Spanish population.

Citing Articles

Genes Variants and the Risk for Restless Legs Syndrome.

Jimenez-Jimenez F, Gomez-Tabales J, Alonso-Navarro H, Rodriguez C, Turpin-Fenoll L, Millan-Pascual J Int J Mol Sci. 2022; 23(23).

PMID: 36499121 PMC: 9739762. DOI: 10.3390/ijms232314795.

Reassessment of candidate gene studies for idiopathic restless legs syndrome in a large genome-wide association study dataset of European ancestry.

Schormair B, Zhao C, Salminen A, Oexle K, Winkelmann J Sleep. 2022; 45(8).

PMID: 35486972 PMC: 9366638. DOI: 10.1093/sleep/zsac098.

Common Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphisms are not Related With the Risk for Restless Legs Syndrome.

Jimenez-Jimenez F, Agundez B, Gomez-Tabales J, Alonso-Navarro H, Turpin-Fenoll L, Millan-Pascual J Front Pharmacol. 2021; 12:618989.

PMID: 33732155 PMC: 7959806. DOI: 10.3389/fphar.2021.618989.

Unraveling the Mysteries of Restless Leg Syndrome.

Memon M, Faiz S, Zaveri M, Perry J, Schuetz T, Cancarevic I Cureus. 2020; 12(10):e10951.

PMID: 33083159 PMC: 7567326. DOI: 10.7759/cureus.10951.

Potential Therapeutic Role of Dietary Supplementation with on the Erectile Function of Obese Rats Fed a Hypercaloric Diet.

Diniz A, Souza I, Dos Santos Ferreira E, de Lima Carvalho M, Barros B, Ferreira P Oxid Med Cell Longev. 2020; 2020:3293065.

PMID: 32685091 PMC: 7345966. DOI: 10.1155/2020/3293065.

References

Kiss J, Hennings E, Zsilla G, Vizi E . A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. Neurochem Int. 1999; 34(4):345-50. DOI: 10.1016/s0197-0186(99)00019-4. View

Patton S, Ponnuru P, Snyder A, Podskalny G, Connor J . Hypoxia-inducible factor pathway activation in restless legs syndrome patients. Eur J Neurol. 2011; 18(11):1329-35. DOI: 10.1111/j.1468-1331.2011.03397.x. View

Baskol G, Korkmaz S, Erdem F, Caniklioglu A, Kocyigit M, Aksu M . Assessment of nitric oxide, advanced oxidation protein products, malondialdehyde, and thiol levels in patients with restless legs syndrome. Sleep Med. 2012; 13(4):414-8. DOI: 10.1016/j.sleep.2011.11.012. View

Allen R, Picchietti D, Hening W, Trenkwalder C, Walters A, Montplaisi J . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003; 4(2):101-19. DOI: 10.1016/s1389-9457(03)00010-8. View

Liu Y . Nitric oxide influences dopaminergic processes. Adv Neuroimmunol. 1996; 6(3):259-64. DOI: 10.1016/s0960-5428(96)00021-6. View

Molina J, Jimenez-Jimenez F, Orti-Pareja M, Navarro J . The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention. Drugs Aging. 1998; 12(4):251-9. DOI: 10.2165/00002512-199812040-00001. View

Winkelmann J, Lichtner P, Schormair B, Uhr M, Hauk S, Stiasny-Kolster K . Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord. 2007; 23(3):350-8. DOI: 10.1002/mds.21647. View

Clemens S, Sawchuk M, Hochman S . Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D3 receptor knockout mice. Neuroscience. 2005; 133(2):353-7. PMC: 2705059. DOI: 10.1016/j.neuroscience.2005.03.002. View

Segovia G, Mora F . Role of nitric oxide in modulating the release of dopamine, glutamate, and GABA in striatum of the freely moving rat. Brain Res Bull. 1998; 45(3):275-9. DOI: 10.1016/s0361-9230(97)00402-4. View

10.

Jimenez-Jimenez F, Alonso-Navarro H, Martinez C, Zurdo M, Turpin-Fenoll L, Millan J . Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. Sleep Med. 2013; 14(4):382-4. DOI: 10.1016/j.sleep.2012.11.009. View

11.

Roco A, Jimenez-Jimenez F, Alonso-Navarro H, Martinez C, Zurdo M, Turpin-Fenoll L . MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome. J Neural Transm (Vienna). 2012; 120(3):463-7. DOI: 10.1007/s00702-012-0897-5. View

12.

West A, Galloway M . Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology. 1998; 36(11-12):1571-81. DOI: 10.1016/s0028-3908(97)00148-2. View

13.

Allen R, Picchietti D, Garcia-Borreguero D, Ondo W, Walters A, Winkelman J . Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014; 15(8):860-73. DOI: 10.1016/j.sleep.2014.03.025. View

14.

Jimenez-Jimenez F, Alonso-Navarro H, Martinez C, Zurdo M, Turpin-Fenoll L, Millan-Pascual J . The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome. Sleep Med. 2014; 15(2):266-8. DOI: 10.1016/j.sleep.2013.08.800. View

15.

Ulfberg J . Treatment of restless legs syndrome with a nitroglycerin patch. Sleep Med. 2012; 13(10):1326. DOI: 10.1016/j.sleep.2012.09.011. View